<![CDATA[Background: Hormonal therapy is widely used in breast cancer treatment, yet its long-term effects on lipid profiles remain a concern, especially regarding the duration of treatment. This study aimed to analyze the association between the type and duration of hormonal therapy and changes in lipid profiles, including total cholesterol, triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL), among breast cancer patients with different menopausal statuses.Methods: A retrospective observational study was conducted using secondary data from 358 female breast cancer patients who received hormonal therapy, such as aromatase inhibitors, selective estrogen receptor modulators, or GnRH agonists, in 2024 at Dr. Moewardi Hospital. Clinical data included the type of hormonal therapy, treatment duration, age, menopausal status, and lipid profile parameters. Data were analyzed using non-parametric tests, with p-values < 0.05 considered statistically significant.Results: A statistically significant association was found between therapy duration and total cholesterol levels (p = 0.023). The highest mean total cholesterol was observed in the 1—2 years group (193.22 ± 58.56 mg/dL), followed by > 2 years (188.04 ± 41.72 mg/dL), and the lowest in < 1 year (174.40 ± 44.91 mg/dL). Post hoc analysis confirmed significant differences between the < 1 year group and both the 1—2 years (p = 0.042) and > 2 years groups (p = 0.032). No statistically significant associations were found between therapy duration and levels of TG, HDL, or LDL, nor between lipid profiles and menopausal status. Conclusions: The duration of hormonal therapy significantly affects total cholesterol levels in breast cancer patients, with longer durations associated with higher levels. These findings emphasize the importance of lipid profile monitoring during extended hormonal therapy to mitigate potential cardiovascular risks.]]>
